Skip Navigation
Menu
Original Research |15 September 1994

2-Chlorodeoxyadenosine-Induced Complete Remissions in Langerhans-Cell Histiocytosis

Alan Saven, MD; Kenneth A. Foon, MD; Lawrence D. Piro, MD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Copyright ©2004 by the American College of Physicians
2004
  • From Scripps Clinic and Research Foundation, La Jolla, California and the University of Kentucky, Lexington, Kentucky. Requests for Reprints: Alan Saven, MD, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, CA 92037. Acknowledgments: The authors thank Mary-Helen Hader for data collection.
×
FULL TEXT
Langerhans-cell histiocytosis results from the proliferation and accumulation of tissue histiocytes, clinically manifested as osteolytic lesions, hypothalamic insufficiency, and seborrheic and vesiculopustular lesions on the scalp, perineum, rectum, and vulva [1]. Treatment has been palliative and includes corticosteroids, alkylating agents, antimetabolites, vinca alkaloids, and irradiation [2]. Combination chemotherapy offers no advantage over the use of single agents and is associated with greater toxicity. 2-Chlorodeoxyadenosine (2-CdA) (cladribine, Leustatin [Ortho Biotech, Raritan, New Jersey]), a purine analog with activity in indolent lymphoproliferative disorders and myeloid leukemias [3, 4], is potently toxic to monocytes in vitro [5]. Because tissue...
FULL TEXT
PDF
Not Available
Citations
Citation

Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-Induced Complete Remissions in Langerhans-Cell Histiocytosis. Ann Intern Med. 1994;121:430–432. doi: https://doi.org/10.7326/0003-4819-121-6-199409150-00006

Download citation file:

© 2020

×
Permissions

Published: Ann Intern Med. 1994;121(6):430-432.

DOI: 10.7326/0003-4819-121-6-199409150-00006

46 Citations

Related Articles
Oral cladribine was more effective than placebo for relapsing–remitting multiple sclerosis
Annals of Internal Medicine; 152 (10): JC5-8
The Hepatopulmonary Syndrome Masquerading as Pulmonary Langerhans-Cell Histiocytosis
Annals of Internal Medicine; 121 (1): 34-36
2-Chlorodeoxyadenosine: A Newer Purine Analog Active in the Treatment of Indolent Lymphoid Malignancies
Annals of Internal Medicine; 120 (9): 784-791
Complete Remissions in Hairy Cell Leukemia with 2-Chlorodeoxyadenosine after Failure with 2-Deoxycoformycin
Annals of Internal Medicine; 119 (4): 278-283
View MoreView Less

Journal Club
Oral cladribine was more effective than placebo for relapsing–remitting multiple sclerosis
Annals of Internal Medicine; 152 (10): JC5-8
View MoreView Less

Related Topics
Interstitial Lung Disease
Pulmonary/Critical Care

Interstitial Lung Disease, Pulmonary/Critical Care.

PubMed Articles
Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?
Mult Scler Relat Disord 2020;
Circulating cell-free BRAFV600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis.
Haematologica 2020.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2020 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×